Malignant Pleural Mesothelioma - Pipeline Review, H1 2016

  • ID: 3753829
  • Report
  • 319 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • ArQule, Inc.
  • Biotecnol, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Morphotek, Inc.
  • MORE
Malignant Pleural Mesothelioma - Pipeline Review, H1 2016

Summary

‘Malignant Pleural Mesothelioma - Pipeline Review, H1 2016’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
- The report reviews pipeline therapeutics for Malignant Pleural Mesothelioma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Malignant Pleural Mesothelioma therapeutics and enlists all their major and minor projects
- The report assesses Malignant Pleural Mesothelioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • ArQule, Inc.
  • Biotecnol, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Morphotek, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Malignant Pleural Mesothelioma Overview

Therapeutics Development

Pipeline Products for Malignant Pleural Mesothelioma - Overview

Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis

Malignant Pleural Mesothelioma - Therapeutics under Development by Companies

Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes

Malignant Pleural Mesothelioma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Malignant Pleural Mesothelioma - Products under Development by Companies

Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes

Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development

Aduro BioTech, Inc.

Advantagene, Inc.

Amphera BV

AnGes MG, Inc.

ArQule, Inc.

Bayer AG

Biogen, Inc.

Bionomics Limited

Biotecnol, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

CanBas Co., Ltd.

Concordia Healthcare Corp.

Eli Lilly and Company

EnGeneIC Ltd

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Genelux Corporation

GlaxoSmithKline Plc

Juno Therapeutics Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Morphotek, Inc.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Oxford BioMedica Plc

Pfizer Inc.

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

Sellas Inc.

Synta Pharmaceuticals Corp.

VasGene Therapeutics, Inc.

Verastem, Inc.

Virttu Biologics Limited

Vyriad

Malignant Pleural Mesothelioma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Ad5-SGE-REIC/Dkk3 - Drug Profile

alisertib - Drug Profile

amatuximab - Drug Profile

anetumab ravtansine - Drug Profile

ascrinvacumab - Drug Profile

bevacizumab - Drug Profile

BG-00001 - Drug Profile

BMS-986148 - Drug Profile

BNC-105 - Drug Profile

CBP-501 - Drug Profile

Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile

Cellular Immunotherapy for Oncology and Infectious Disease - Drug Profile

CRS-207 - Drug Profile

CSG-MESO - Drug Profile

defactinib hydrochloride - Drug Profile

FP-1039 - Drug Profile

galinpepimut-S - Drug Profile

ganetespib - Drug Profile

GEN-0101 - Drug Profile

Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile

Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile

GLONC-1 - Drug Profile

GSK-2256098 - Drug Profile

HSV-1716 - Drug Profile

iCasp9M28z - Drug Profile

JTCR-016 - Drug Profile

LY-3023414 - Drug Profile

MesoCancerVac - Drug Profile

MesoCART - Drug Profile

Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile

napabucasin - Drug Profile

NGR-hTNF - Drug Profile

nintedanib - Drug Profile

nivolumab - Drug Profile

Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma - Drug Profile

OXB-301 - Drug Profile

pegargiminase - Drug Profile

pembrolizumab - Drug Profile

porfimer sodium - Drug Profile

rAd-IFN - Drug Profile

S-588210 - Drug Profile

Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile

TargomiRs - Drug Profile

Tb-535 - Drug Profile

tivantinib - Drug Profile

trabectedin - Drug Profile

Vas-01 - Drug Profile

VS-5584 - Drug Profile

Malignant Pleural Mesothelioma - Recent Pipeline Updates

Malignant Pleural Mesothelioma - Dormant Projects

Malignant Pleural Mesothelioma - Discontinued Products

Malignant Pleural Mesothelioma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Malignant Pleural Mesothelioma, H1 2016

Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H1 2016

Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Biogen, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Biotecnol, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2016

Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Concordia Healthcare Corp., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Eli Lilly and Company, H1 2016

Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2016

Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H1 2016

Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Sellas Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H1 2016

Malignant Pleural Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H1 2016

Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2016

Malignant Pleural Mesothelioma - Pipeline by Vyriad, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2016

Malignant Pleural Mesothelioma - Dormant Projects, H1 2016

Malignant Pleural Mesothelioma - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Malignant Pleural Mesothelioma, H1 2016

Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Aduro BioTech, Inc.
Advantagene, Inc.
Amphera BV
AnGes MG, Inc.
ArQule, Inc.
Bayer AG
Biogen, Inc.
Bionomics Limited
Biotecnol, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CanBas Co., Ltd.
Concordia Healthcare Corp.
Eli Lilly and Company
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline Plc
Juno Therapeutics Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Oxford BioMedica Plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Sellas Inc.
Synta Pharmaceuticals Corp.
VasGene Therapeutics, Inc.
Verastem, Inc.
Virttu Biologics Limited
Vyriad
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll